Fully humanized antibody, single-chain antibody and antigen binding fragment of targeted BAFF-R antigen

The invention provides a fully humanized antibody, a single-chain antibody and an antigen binding fragment of a targeted BAFF-R antigen, the fully humanized antibody, the single-chain antibody and the antigen binding fragment of the targeted BAFF-R antigen are combined with the BAFF-R antigen with h...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LI TONG, TAN TAOCHAO, JIA XIANGYIN, WEI QIAOE, XIE MENG, ZHANG QIANQIAN, LIU JIANWEI
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention provides a fully humanized antibody, a single-chain antibody and an antigen binding fragment of a targeted BAFF-R antigen, the fully humanized antibody, the single-chain antibody and the antigen binding fragment of the targeted BAFF-R antigen are combined with the BAFF-R antigen with high affinity and high specificity, and compared with a heterologous antibody, the fully humanized antibody, the single-chain antibody and the antigen binding fragment have lower immunogenicity and can be used for preparing the BAFF-R antigen. The method has good application potential in development of antibody drugs and cell therapy drugs. 本发明提供了一种靶向BAFF-R抗原的全人源抗体、单链抗体、抗原结合片段，所述靶向BAFF-R抗原的全人源抗体、单链抗体、抗原结合片段以高亲和力和高特异性结合BAFF-R抗原，且与异源抗体相比，具有更低的免疫原性，在抗体药物及细胞治疗药物开发上有很好的应用潜力。